Back icon Back
Freenome

Freenome

Company

By Sriparna Roy
Feb 15 (Reuters) – Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple early-stage cancers. The company did not disclose the valuation at which the funds were raised.

https://www.reuters.com/business/healthcare-pharmaceuticals/cancer-test-firm-freenome-raises-254-mln-fresh-funding-2024-02-15/

Date

Feb 15, 2024

Category

healthcare

Lead investor

Country Icon Roche Venture Fund

Stage

Series E

Size

$254M

Explore similar Investments to Freenome

Company
Size
Date
Lead Investor
Press
Pallet

Pallet

Company
$27M
May 27, 2025
Investor General Catalyst
Source
Podcastle

Podcastle

Company
$13.5M
Feb 1, 2024
Investor Mosaic Ventures
Source
Campfire

Campfire

Company
$35M
Jun 30, 2025
Investor Accel
Source
Endeavor

Endeavor

Company
$7M
Oct 31, 2024
Investor Craft Ventures
Source
Ditto

Ditto

Company
$82M
Mar 12, 2025
Investor Acrew Capital
Source
Slope

Slope

Company
$65M
Jul 17, 2024
Investor J.P. Morgan
Source
Mynt

Mynt

Company
$23M
Dec 11, 2024
Investor Incore
Source
Mura

Mura

Company
$6M
May 20, 2025
Investor Lerer Hippeau
Source
Tines

Tines

Company
$50M
Apr 24, 2024
Investor Felicis
Source
Blok

Blok

Company
$5M
Jul 12, 2025
Investor MaC Venture Capital
Source
Finofo

Finofo

Company
$3.3M
Jun 10, 2025
Investor Watertower Ventures
Source
Hume AI

Hume AI

Company
$50M
Mar 25, 2024
Investor EQT Ventures
Source

Startups, venture funds
& everything in between.

Explore verified companies, top VCs, and practical guides built to help you raise, invest, and grow faster.
Made by Omnius. For builders, by builders.
Venture Funds Startups Investments Events Programs Case Studies Interviews & Lectures Reports & Publications